| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 34 | 2021 | 754 | 6.130 |
Why?
|
| Brain Neoplasms | 38 | 2020 | 647 | 5.760 |
Why?
|
| Neoplasm Metastasis | 21 | 2021 | 220 | 3.470 |
Why?
|
| Neoplastic Stem Cells | 13 | 2019 | 98 | 3.360 |
Why?
|
| MicroRNAs | 11 | 2021 | 189 | 2.930 |
Why?
|
| Gene Expression Regulation, Neoplastic | 26 | 2021 | 265 | 2.740 |
Why?
|
| Prostatic Neoplasms | 14 | 2016 | 476 | 2.560 |
Why?
|
| Bone Neoplasms | 7 | 2021 | 117 | 2.340 |
Why?
|
| Neoplasms | 15 | 2020 | 762 | 2.050 |
Why?
|
| Radiosurgery | 19 | 2020 | 362 | 2.000 |
Why?
|
| Cell Line, Tumor | 35 | 2021 | 727 | 1.920 |
Why?
|
| Mice | 34 | 2021 | 2527 | 1.770 |
Why?
|
| Signal Transduction | 16 | 2020 | 688 | 1.760 |
Why?
|
| Animals | 49 | 2021 | 7594 | 1.730 |
Why?
|
| Genes, Tumor Suppressor | 7 | 2015 | 34 | 1.700 |
Why?
|
| Microglia | 3 | 2020 | 68 | 1.670 |
Why?
|
| Lung Neoplasms | 10 | 2021 | 429 | 1.670 |
Why?
|
| Mice, Nude | 16 | 2021 | 290 | 1.420 |
Why?
|
| Humans | 95 | 2021 | 32840 | 1.320 |
Why?
|
| Exosomes | 3 | 2021 | 45 | 1.310 |
Why?
|
| Cell Proliferation | 14 | 2019 | 604 | 1.230 |
Why?
|
| Apoptosis | 10 | 2018 | 363 | 1.170 |
Why?
|
| Nicotine | 2 | 2021 | 177 | 1.130 |
Why?
|
| Macrophages | 3 | 2017 | 194 | 1.110 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 599 | 1.100 |
Why?
|
| Neoplasm Proteins | 4 | 2020 | 145 | 1.060 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2018 | 19 | 1.050 |
Why?
|
| Female | 55 | 2021 | 20293 | 1.020 |
Why?
|
| Neoplasm Invasiveness | 11 | 2016 | 193 | 1.000 |
Why?
|
| Cell Cycle Proteins | 6 | 2018 | 56 | 0.950 |
Why?
|
| Kangai-1 Protein | 4 | 2011 | 4 | 0.920 |
Why?
|
| Promoter Regions, Genetic | 7 | 2019 | 209 | 0.910 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2015 | 71 | 0.900 |
Why?
|
| Neovascularization, Pathologic | 5 | 2017 | 80 | 0.770 |
Why?
|
| Magnetic Field Therapy | 2 | 2019 | 17 | 0.750 |
Why?
|
| Calcium Channels, T-Type | 2 | 2019 | 29 | 0.740 |
Why?
|
| rho GTP-Binding Proteins | 2 | 2015 | 11 | 0.740 |
Why?
|
| Disease Progression | 10 | 2019 | 594 | 0.740 |
Why?
|
| Wnt Proteins | 3 | 2012 | 17 | 0.720 |
Why?
|
| Calcium | 3 | 2019 | 323 | 0.680 |
Why?
|
| Receptors, Cell Surface | 4 | 2015 | 69 | 0.670 |
Why?
|
| Neutrophils | 1 | 2021 | 110 | 0.650 |
Why?
|
| Immunity, Innate | 1 | 2020 | 76 | 0.630 |
Why?
|
| Gene Expression Profiling | 7 | 2019 | 316 | 0.630 |
Why?
|
| Activating Transcription Factor 3 | 2 | 2011 | 7 | 0.600 |
Why?
|
| Connexins | 1 | 2019 | 3 | 0.600 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2019 | 5 | 0.600 |
Why?
|
| Lung | 1 | 2021 | 266 | 0.590 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2019 | 384 | 0.580 |
Why?
|
| Duffy Blood-Group System | 3 | 2007 | 4 | 0.580 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 34 | 0.560 |
Why?
|
| Up-Regulation | 9 | 2018 | 191 | 0.550 |
Why?
|
| Male | 35 | 2020 | 19675 | 0.540 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2008 | 70 | 0.510 |
Why?
|
| Osteonectin | 1 | 2016 | 17 | 0.490 |
Why?
|
| Bone Morphogenetic Protein 7 | 2 | 2016 | 17 | 0.480 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 1014 | 0.480 |
Why?
|
| RNA, Untranslated | 1 | 2016 | 10 | 0.480 |
Why?
|
| Models, Biological | 6 | 2019 | 392 | 0.480 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2015 | 213 | 0.470 |
Why?
|
| GTP-Binding Proteins | 2 | 2006 | 24 | 0.470 |
Why?
|
| Stilbenes | 2 | 2016 | 21 | 0.460 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2005 | 11 | 0.460 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2015 | 5 | 0.450 |
Why?
|
| Neoplasm Transplantation | 7 | 2018 | 72 | 0.450 |
Why?
|
| beta Catenin | 2 | 2012 | 37 | 0.440 |
Why?
|
| Cyclooxygenase 2 | 1 | 2015 | 50 | 0.440 |
Why?
|
| NF-kappa B | 2 | 2014 | 83 | 0.440 |
Why?
|
| Astrocytes | 2 | 2019 | 57 | 0.420 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2014 | 17 | 0.420 |
Why?
|
| Cranial Irradiation | 6 | 2020 | 93 | 0.410 |
Why?
|
| Salvage Therapy | 6 | 2020 | 134 | 0.410 |
Why?
|
| Survival Analysis | 10 | 2020 | 486 | 0.400 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2016 | 78 | 0.400 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2019 | 115 | 0.400 |
Why?
|
| Receptors, Notch | 1 | 2013 | 16 | 0.390 |
Why?
|
| Transplantation, Heterologous | 5 | 2018 | 122 | 0.390 |
Why?
|
| Prognosis | 11 | 2020 | 1545 | 0.390 |
Why?
|
| Genes, Neoplasm | 2 | 2010 | 17 | 0.380 |
Why?
|
| Drug Design | 2 | 2012 | 45 | 0.380 |
Why?
|
| Fatty Acid Synthesis Inhibitors | 1 | 2012 | 3 | 0.370 |
Why?
|
| Patents as Topic | 1 | 2012 | 2 | 0.370 |
Why?
|
| Epithelial Cells | 2 | 2010 | 129 | 0.370 |
Why?
|
| Rats | 7 | 2013 | 1609 | 0.370 |
Why?
|
| Transfection | 7 | 2015 | 185 | 0.370 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2012 | 72 | 0.360 |
Why?
|
| Endothelial Cells | 3 | 2010 | 197 | 0.360 |
Why?
|
| Mice, SCID | 6 | 2013 | 71 | 0.360 |
Why?
|
| Glucuronosyltransferase | 1 | 2011 | 5 | 0.360 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2015 | 255 | 0.350 |
Why?
|
| Stromal Cells | 1 | 2011 | 67 | 0.350 |
Why?
|
| Middle Aged | 24 | 2020 | 12146 | 0.340 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2010 | 35 | 0.330 |
Why?
|
| Sterol Regulatory Element Binding Proteins | 1 | 2010 | 1 | 0.330 |
Why?
|
| Sesquiterpenes | 1 | 2010 | 5 | 0.330 |
Why?
|
| Electromagnetic Fields | 3 | 2020 | 28 | 0.330 |
Why?
|
| Glioblastoma | 3 | 2018 | 157 | 0.330 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2010 | 19 | 0.320 |
Why?
|
| Mammary Glands, Human | 1 | 2010 | 14 | 0.310 |
Why?
|
| Blotting, Western | 7 | 2015 | 290 | 0.310 |
Why?
|
| STAT3 Transcription Factor | 2 | 2021 | 23 | 0.310 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 59 | 0.310 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2020 | 61 | 0.300 |
Why?
|
| Fibroblasts | 1 | 2010 | 115 | 0.300 |
Why?
|
| Membrane Glycoproteins | 2 | 2006 | 98 | 0.300 |
Why?
|
| Treatment Outcome | 12 | 2019 | 3441 | 0.300 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2008 | 2 | 0.290 |
Why?
|
| Retrospective Studies | 15 | 2020 | 3708 | 0.290 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2008 | 6 | 0.280 |
Why?
|
| Liver Neoplasms | 2 | 2020 | 155 | 0.280 |
Why?
|
| Aged | 18 | 2020 | 10557 | 0.280 |
Why?
|
| Transcription Factors | 3 | 2019 | 178 | 0.270 |
Why?
|
| Enzyme Activation | 4 | 2020 | 133 | 0.260 |
Why?
|
| RNA Interference | 4 | 2013 | 77 | 0.250 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 113 | 0.250 |
Why?
|
| Membrane Proteins | 4 | 2018 | 251 | 0.250 |
Why?
|
| Vitamin E | 1 | 2006 | 19 | 0.240 |
Why?
|
| Brain | 3 | 2018 | 948 | 0.230 |
Why?
|
| Cell Adhesion | 3 | 2016 | 103 | 0.230 |
Why?
|
| Cell Communication | 2 | 2017 | 29 | 0.230 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 497 | 0.230 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 155 | 0.230 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 3 | 2010 | 6 | 0.230 |
Why?
|
| Cell Movement | 5 | 2018 | 173 | 0.230 |
Why?
|
| Smoking | 2 | 2021 | 531 | 0.230 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2010 | 40 | 0.230 |
Why?
|
| Blood-Brain Barrier | 2 | 2015 | 50 | 0.220 |
Why?
|
| Reactive Oxygen Species | 4 | 2015 | 164 | 0.220 |
Why?
|
| Mesenchymal Stem Cells | 2 | 2017 | 182 | 0.220 |
Why?
|
| Mice, Knockout | 2 | 2021 | 458 | 0.210 |
Why?
|
| Melanoma | 4 | 2019 | 165 | 0.210 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2016 | 36 | 0.210 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2015 | 27 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 180 | 0.210 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 4034 | 0.200 |
Why?
|
| Pesticides | 1 | 2016 | 196 | 0.200 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 169 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2016 | 231 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 240 | 0.190 |
Why?
|
| Transients and Migrants | 1 | 2016 | 298 | 0.190 |
Why?
|
| Cytokines | 2 | 2017 | 247 | 0.190 |
Why?
|
| Transcription, Genetic | 3 | 2016 | 134 | 0.190 |
Why?
|
| Solidago | 1 | 2002 | 1 | 0.180 |
Why?
|
| Phytotherapy | 1 | 2002 | 37 | 0.180 |
Why?
|
| Osteoclasts | 1 | 2021 | 25 | 0.180 |
Why?
|
| Cells, Cultured | 2 | 2015 | 821 | 0.170 |
Why?
|
| Plant Extracts | 1 | 2002 | 61 | 0.170 |
Why?
|
| Receptors, Estrogen | 1 | 2021 | 106 | 0.170 |
Why?
|
| Receptor, erbB-2 | 2 | 2019 | 65 | 0.170 |
Why?
|
| Gene Knockdown Techniques | 4 | 2019 | 77 | 0.170 |
Why?
|
| Neutrophil Infiltration | 1 | 2021 | 12 | 0.170 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2013 | 98 | 0.170 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 154 | 0.170 |
Why?
|
| Citric Acid Cycle | 1 | 2020 | 11 | 0.170 |
Why?
|
| Protein Transport | 2 | 2017 | 72 | 0.170 |
Why?
|
| Chemokine CCL20 | 1 | 2020 | 6 | 0.170 |
Why?
|
| Cell Survival | 4 | 2020 | 281 | 0.170 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2020 | 18 | 0.170 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 22 | 0.160 |
Why?
|
| Antigens, Differentiation | 1 | 2020 | 25 | 0.160 |
Why?
|
| DNA Methylation | 2 | 2016 | 145 | 0.160 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2020 | 37 | 0.160 |
Why?
|
| Lipogenesis | 2 | 2010 | 18 | 0.160 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 83 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 3 | 2006 | 160 | 0.160 |
Why?
|
| Hispanic Americans | 1 | 2016 | 930 | 0.160 |
Why?
|
| Syndecan-1 | 1 | 2019 | 12 | 0.160 |
Why?
|
| Plasma Cells | 1 | 2019 | 11 | 0.160 |
Why?
|
| Adult | 10 | 2020 | 9576 | 0.150 |
Why?
|
| HMGA2 Protein | 1 | 2019 | 13 | 0.150 |
Why?
|
| Cyclophosphamide | 2 | 2010 | 42 | 0.150 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 36 | 0.150 |
Why?
|
| Chalcone | 1 | 2019 | 3 | 0.150 |
Why?
|
| Cystatin A | 1 | 2019 | 9 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 65 | 0.150 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2019 | 11 | 0.150 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2019 | 19 | 0.150 |
Why?
|
| Porifera | 1 | 2018 | 1 | 0.150 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 39 | 0.150 |
Why?
|
| Myeloid Cells | 1 | 2019 | 39 | 0.150 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2018 | 7 | 0.150 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 21 | 0.150 |
Why?
|
| Tyrosine | 1 | 2018 | 23 | 0.150 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 20 | 0.150 |
Why?
|
| Disulfides | 1 | 2018 | 38 | 0.150 |
Why?
|
| Computational Biology | 2 | 2016 | 94 | 0.140 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 52 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 102 | 0.140 |
Why?
|
| Acidosis | 2 | 2015 | 18 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 88 | 0.140 |
Why?
|
| Survival Rate | 4 | 2020 | 895 | 0.140 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 300 | 0.140 |
Why?
|
| Down-Regulation | 1 | 2018 | 134 | 0.140 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 471 | 0.130 |
Why?
|
| Cell Separation | 1 | 2017 | 90 | 0.130 |
Why?
|
| Medicare | 1 | 2018 | 213 | 0.130 |
Why?
|
| Nervous System Neoplasms | 1 | 2017 | 8 | 0.130 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2016 | 4 | 0.130 |
Why?
|
| Caspase 3 | 2 | 2010 | 39 | 0.130 |
Why?
|
| Meningeal Neoplasms | 1 | 2017 | 50 | 0.130 |
Why?
|
| Mitochondria | 2 | 2016 | 208 | 0.130 |
Why?
|
| Base Sequence | 4 | 2016 | 249 | 0.130 |
Why?
|
| bcl-X Protein | 1 | 2016 | 5 | 0.120 |
Why?
|
| Azacitidine | 1 | 2016 | 28 | 0.120 |
Why?
|
| Alternative Splicing | 1 | 2016 | 34 | 0.120 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 54 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 2285 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 74 | 0.120 |
Why?
|
| Systems Biology | 1 | 2016 | 9 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2015 | 3 | 0.120 |
Why?
|
| Nucleotides | 1 | 2015 | 16 | 0.120 |
Why?
|
| RNA, Small Interfering | 3 | 2019 | 113 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2005 | 20 | 0.110 |
Why?
|
| Receptors, CCR7 | 1 | 2015 | 4 | 0.110 |
Why?
|
| Sarcoma | 1 | 2016 | 71 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 108 | 0.110 |
Why?
|
| Oncogene Protein v-akt | 1 | 2014 | 4 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 326 | 0.110 |
Why?
|
| Caspases | 2 | 2006 | 36 | 0.110 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 25 | 0.100 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 25 | 0.100 |
Why?
|
| NIH 3T3 Cells | 1 | 2013 | 43 | 0.100 |
Why?
|
| Culture Media, Conditioned | 1 | 2013 | 47 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 40 | 0.100 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 47 | 0.100 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2012 | 1 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2013 | 50 | 0.100 |
Why?
|
| Stem Cell Niche | 1 | 2013 | 27 | 0.100 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 44 | 0.100 |
Why?
|
| Inflammation | 1 | 2016 | 536 | 0.100 |
Why?
|
| DNA Damage | 1 | 2012 | 94 | 0.090 |
Why?
|
| Protein Isoforms | 2 | 2016 | 59 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2020 | 226 | 0.090 |
Why?
|
| Genes, myc | 1 | 2012 | 5 | 0.090 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2011 | 3 | 0.090 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 12 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 9 | 0.090 |
Why?
|
| Hymecromone | 1 | 2011 | 1 | 0.090 |
Why?
|
| Chemokines | 1 | 2012 | 33 | 0.090 |
Why?
|
| Time Factors | 2 | 2017 | 2190 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2011 | 6 | 0.090 |
Why?
|
| Drug Delivery Systems | 2 | 2010 | 105 | 0.080 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 163 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 103 | 0.080 |
Why?
|
| Luciferases, Renilla | 1 | 2010 | 1 | 0.080 |
Why?
|
| Genes, Reporter | 1 | 2010 | 39 | 0.080 |
Why?
|
| Drug Synergism | 1 | 2010 | 64 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2010 | 61 | 0.080 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 356 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2010 | 67 | 0.080 |
Why?
|
| Mesoderm | 1 | 2010 | 13 | 0.080 |
Why?
|
| Receptor, Adenosine A3 | 1 | 2009 | 1 | 0.080 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2010 | 23 | 0.080 |
Why?
|
| Aldehyde Reductase | 1 | 2009 | 3 | 0.080 |
Why?
|
| Aldehydes | 1 | 2009 | 4 | 0.080 |
Why?
|
| Malondialdehyde | 1 | 2009 | 10 | 0.080 |
Why?
|
| Gene Expression | 1 | 2010 | 335 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2009 | 29 | 0.070 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2008 | 3 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 9 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2008 | 14 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2008 | 32 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 37 | 0.070 |
Why?
|
| Carcinogens | 1 | 2008 | 35 | 0.070 |
Why?
|
| Spheroids, Cellular | 2 | 2018 | 38 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2008 | 3 | 0.070 |
Why?
|
| Lipids | 1 | 2009 | 229 | 0.070 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 43 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 80 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2008 | 107 | 0.070 |
Why?
|
| Restriction Mapping | 1 | 2006 | 14 | 0.060 |
Why?
|
| Plasmids | 1 | 2006 | 46 | 0.060 |
Why?
|
| Mammary Glands, Animal | 1 | 2007 | 64 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 84 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 11 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2009 | 186 | 0.060 |
Why?
|
| Caspases, Initiator | 1 | 2006 | 1 | 0.060 |
Why?
|
| Tocopherols | 1 | 2006 | 3 | 0.060 |
Why?
|
| T-Box Domain Proteins | 1 | 2006 | 14 | 0.060 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2006 | 23 | 0.060 |
Why?
|
| Heterozygote | 1 | 2006 | 61 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 96 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 287 | 0.060 |
Why?
|
| Risk Factors | 3 | 2019 | 3981 | 0.060 |
Why?
|
| Alleles | 1 | 2006 | 253 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 563 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 764 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 457 | 0.050 |
Why?
|
| Proteins | 1 | 2005 | 146 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2015 | 74 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2019 | 2330 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 877 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2018 | 1844 | 0.050 |
Why?
|
| Cell Division | 1 | 2002 | 95 | 0.040 |
Why?
|
| North Carolina | 1 | 2016 | 1548 | 0.040 |
Why?
|
| Phosphoserine | 1 | 2020 | 8 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2020 | 67 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2020 | 54 | 0.040 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2019 | 21 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 19 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2019 | 10 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2019 | 10 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2019 | 11 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 315 | 0.040 |
Why?
|
| Radiometry | 1 | 2019 | 40 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 51 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 80 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 169 | 0.040 |
Why?
|
| Histone Deacetylases | 1 | 2018 | 8 | 0.040 |
Why?
|
| Culture Techniques | 1 | 2018 | 14 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 282 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 55 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2018 | 36 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 99 | 0.040 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2018 | 6 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2018 | 41 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 35 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 308 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 70 | 0.030 |
Why?
|
| Nomograms | 1 | 2017 | 35 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 158 | 0.030 |
Why?
|
| Hearing Tests | 1 | 2017 | 13 | 0.030 |
Why?
|
| Brain Death | 1 | 2017 | 27 | 0.030 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2016 | 2 | 0.030 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2016 | 2 | 0.030 |
Why?
|
| Cytosol | 1 | 2016 | 22 | 0.030 |
Why?
|
| Lysine | 1 | 2016 | 23 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2016 | 16 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 148 | 0.030 |
Why?
|
| RNA Precursors | 1 | 2016 | 2 | 0.030 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2016 | 2 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 15 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 40 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 99 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2016 | 67 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1239 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2016 | 107 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 69 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 201 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 460 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 34 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2016 | 78 | 0.030 |
Why?
|
| Deoxycytidine Kinase | 1 | 2015 | 2 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 116 | 0.030 |
Why?
|
| Guanosine Triphosphate | 1 | 2015 | 8 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2015 | 12 | 0.030 |
Why?
|
| Nucleosides | 1 | 2015 | 9 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 369 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 32 | 0.030 |
Why?
|
| Estrogens | 1 | 2016 | 169 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2015 | 11 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2016 | 94 | 0.030 |
Why?
|
| Proteome | 1 | 2015 | 41 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 71 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 91 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2016 | 138 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2016 | 499 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 205 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 52 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 105 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2012 | 11 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2012 | 13 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 20 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 499 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 91 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 99 | 0.020 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Frizzled Receptors | 1 | 2012 | 5 | 0.020 |
Why?
|
| TCF Transcription Factors | 1 | 2012 | 8 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 1307 | 0.020 |
Why?
|
| United States | 1 | 2018 | 4118 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2009 | 19 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 36 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 42 | 0.020 |
Why?
|
| Rhodanine | 1 | 2009 | 1 | 0.020 |
Why?
|
| Thiazolidines | 1 | 2009 | 2 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2009 | 4 | 0.020 |
Why?
|
| Lipid Peroxides | 1 | 2009 | 8 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2009 | 21 | 0.020 |
Why?
|
| Palmitic Acid | 1 | 2009 | 11 | 0.020 |
Why?
|
| Adenosine | 1 | 2009 | 59 | 0.020 |
Why?
|
| Response Elements | 1 | 2009 | 17 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 152 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2009 | 241 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 475 | 0.020 |
Why?
|
| Dimerization | 1 | 2005 | 23 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2005 | 28 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 89 | 0.010 |
Why?
|